Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Elite Pharmaceuticals Inc (ELTP)
Price$0.2475Cached quote
Net income
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total cash / debt
CashTotal debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $148.9M | $84.0M | $56.6M | $34.2M | $32.3M | $25.4M | $18.0M | $7.6M | $7.5M | $9.6M | $12.5M | $5.0M | $4.6M | $3.4M | $2.4M | $4.3M |
| Gross profit | $75.0M | $40.1M | $26.4M | $16.6M | $14.8M | $11.9M | $8.0M | $2.9M | $3.9M | $3.7M | $8.0M | $2.0M | $1.4M | $1.1M | $1.4M | $1.6M |
| Gross margin | 50.40% | 47.70% | 46.55% | 48.58% | 45.86% | 46.76% | 44.34% | 37.89% | 52.93% | 38.80% | 64.12% | 39.91% | 29.67% | 31.98% | 58.18% | 37.29% |
| Research & development | $5.7M | $8.0M | $6.9M | $6.2M | $4.1M | $5.1M | $5.5M | $7.6M | $9.6M | $8.3M | $12.4M | $14.7M | $4.0M | $975,250 | $1.7M | $1.4M |
| Operating expenses | $25.9M | $20.5M | $15.6M | $12.9M | $9.7M | $9.8M | $10.3M | $12.0M | $13.0M | $11.1M | $16.3M | $18.5M | $6.6M | $2.7M | $3.4M | $2.5M |
| Operating income | $49.1M | $19.6M | $10.8M | $3.7M | $5.1M | $2.1M | −$2.3M | −$9.2M | −$9.1M | −$7.4M | −$8.3M | −$16.5M | −$5.3M | −$1.6M | −$2.0M | −$885,760 |
| Operating margin | 32.99% | 23.32% | 19.05% | 10.76% | 15.72% | 8.29% | −12.70% | −121.01% | −121.35% | −76.32% | −66.54% | −329.14% | −114.83% | −45.93% | −81.11% | −20.76% |
| EBITDA | $50.2M | $20.8M | $12.1M | $5.0M | $6.3M | $3.4M | −$965,613 | −$7.9M | −$8.1M | −$6.6M | −$7.7M | −$15.9M | −$4.8M | −$1.1M | −$1.5M | −$402,287 |
| EBITDA margin | 33.71% | 24.78% | 21.39% | 14.50% | 19.47% | 13.47% | −5.37% | −104.40% | −107.99% | −68.91% | −61.21% | −317.53% | −104.97% | −33.49% | −61.14% | −9.43% |
| Net income | $44.9M | −$4.3M | $20.1M | $3.6M | $8.9M | $5.1M | −$2.2M | −$9.3M | −$3.7M | $3.8M | −$683,012 | $5.2M | −$41.3M | $1.5M | −$15.1M | −$13.6M |
| Net profit margin | 30.14% | −5.13% | 35.51% | 10.43% | 27.58% | 20.05% | −12.45% | −122.60% | −49.25% | 39.54% | −5.46% | 104.09% | −896.71% | 43.72% | −621.19% | −318.38% |
| Basic EPSper basic share | $0.04 | $0.00 | $0.02 | $0.00 | $0.01 | $0.01 | $0.00 | -$0.01 | $0.00 | $0.03 | -$0.01 | $0.05 | -$0.21 | $0.00 | -$0.06 | -$0.14 |
| Diluted EPSper diluted share | $0.03 | $0.00 | $0.02 | $0.00 | $0.01 | $0.00 | $0.00 | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.02 | -$0.21 | $0.00 | -$0.06 | -$0.14 |
Owners
Reported shareholders
≈0.40%of listed shares
ELITE PHARMACEUTICALS INC /NV/4.3M shares · Aug 25, 2025
View holders
| Holder | % owned |
|---|---|
ELITE PHARMACEUTICALS INC /NV/ | ≈0.40%4.3M shares |
Plassche Douglas | ≈0.32%3.5M shares |
Kirkov Kirko | ≈<0.01%16.37K shares |
KELLEHER FINANCIAL ADVISORS | <0.01%1K shares |
Percentages use 1.08B shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 2, 2025Form 4 | Plassche DouglasEVP Operations | Sellcommon stock | 800.0K | $0.62 | $496.0K | 3.50M |
| Aug 22, 2025Form 4 | ELITE PHARMACEUTICALS INC /NV/EVP Operations | SellCommon Stock | 500.0K | $0.52 | $260.0K | 1.80M |
| Jul 10, 2025Form 4 | Kirkov KirkoChief Commercial Officer | BuyCommon Stock | 16.4K | $0.59 | $9.7K | 16.4K |
| Jul 8, 2025Form 4 | Plassche DouglasEVP Operations | SellStock Options (right to buy) | 200.0K | $0.58 | $116.0K | 2.30M |
| Oct 24, 2024Form 4 | Plassche DouglasSVP of Operations | SellCommon Stock | 333.9K | $0.51 | $170.3K | 0 |